1	Clinical and neurogenetic characterisation of autosomal recessive RBL2-associated
2	progressive neurodevelopmental disorder.
3	Gabriel Aughey ^{1*} , Elisa Cali ^{2*} , Reza Maroofian ^{2*} , Maha S Zaki ³ , Alistair T Pagnamenta ⁴ ,
4	Fatima Rahman ⁵ , Lara Menzies ⁶ , Anum Shafique ⁷ , Mohnish Suri ^{8,9} , Emmanuel Roze ¹⁰ ,
5	Mohammed Aguennouz ¹¹ , Zouiri Ghizlane ¹² , Saadia Maryam Saadi ¹³ , Zafar Ali ¹⁴ , Uzma
6	Abdulllah ¹⁵ , Huma Arshad Cheema ¹⁶ , Muhammad Nadeem Anjum ¹⁶ , Godelieve Morel ¹⁷ ,
7	Robert McFarland ^{18,19} , Umut Altunoglu ²⁰ , Verena Kraus ²¹ , Moneef Shoukier ²² , David
8	Murphy ²³ , Kristina Flemming ²⁴ , Hilde Yttervik ²⁵ , Hajar Rhouda ¹² , Gaetan Lesca ²⁶ , Bibi Nazia
9	Murtaza ²⁷ , Mujaddad Ur Rehman ²⁷ , SYNAPS Study Group ² , Genomics England
10	Consortium ²⁸ , Go Hun Seo ²⁹ , Christian Beetz ³⁰ , Hülya Kayserili ²⁰ , Yamna Krioulie ¹² , Wendy
11	K Chung ³¹ , Sadaf Naz ⁷ , Shazia Maqbool ⁵ , Joseph Gleeson ^{32,33} , Shahid Mahmood Baig ^{34,35} ,
12	Stephanie Efthymiou ² , Jenny C Taylor ⁴ , Mariasavina Severino ³⁶ , James EC Jepson ^{1#} , Henry
13	Houlden ^{2#}
14	
15	Author affiliations:
16	1. Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of
17	Neurology, London, UK
18	2. Department of Neuromuscular diseases, UCL Queen Square Institute of Neurology,
19	London, UK
20	3. Department of Clinical Genetics, Human Genetics and Genome Research Institute,
21	National Research Centre, Dokki, Cairo 12622, Egypt
22	4. NIHR Oxford Biomedical Research Centre, Centre for Human Genetics, University of
23	Oxford, Oxford, OX3 9DU, UK
24	5. Department of Developmental-Behavioral Pediatrics, The Children's Hospital, University
25	of Child Health Sciences (UCHS-CH), Lahore 54600, Pakistan
26	6. Department of Clinical Genetics, Great Ormond Street Hospital for Children NHS
27	NOTE: THIS DESTINATED HIS NEW AREA WINS THE BEHICEN BY DEER review and should not be used to guide clinical practice.

54	Germany
53	21. Department of Pediatrics and Social Pediatrics, TUM School of Medicine, Munich,
52	Turkey
51	20. Medical Genetics Department, School of Medicine (KUSoM), Koç University, Istanbul,
50	Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE2 4HH, UK
49	19. NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne
48	4HH, UK
47	Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2
46	18. Wellcome Centre for Mitochondrial Research, Translational and Clinical Research
45	17. Service de Génétique Médicale, CHU Felix Guyon, France
44	Hospital and University of Child Health Sciences Lahore Pakistan
43	16. Department of Paediatric Gastroenterology Hepatology and Genetic diseases Children's
42	University Rawalpindi, Rawalpindi 46300, Pakistan
41	15. University Institute of Biochemistry and Biotechnology (UIBB), PMAS-Arid Agriculture
40	Pakhtunkhwa 19120, Pakistan
39	14. Centre for Biotechnology and Microbiology, University of Swat, Charbagh, Swat, Khyber
38	13. Human Molecular Genetics Laboratory, NIBGE-PIEAS, Faisalabad, Pakistan
37	Hospital, BP 6527 Rabat, Morocco
36	12. Unit of Neuropediatrics and Neurometabolism, Pediatric Department 2, Rabat Children's
35	11. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
34	Paris, France
33	10. Sorbonne University, INSERM, CNRS, Paris Brain Institute, Salpêtrière Hospital / AP-HP,
32	Nottingham, UK
31	9. Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust.
30	Trust. Nottingham. UK
29	8. UK National Paediatric Ataxia Telangiectasia Clinic. Nottingham University Hospitals NHS
28	7 School of Biological Sciences, University of the Puniab, Labore 54500, Pakistan

- 55 22. Department of Molecular Genetics, Prenatal Medicine Munich, Munich, Germany.
- 56 23. Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of
- 57 Neurology, University College London, United Kingdom
- 58 24. Department of Pediatric Rehabilitation, University Hospital Northern Norway
- 59 25. Department of Medical Genetics, University Hospital of North Norway, Tromsø, Norway
- 60 26. Genetics Department, Hospices Civils de Lyon, Lyon, France; GENDEV Team, CRNL,
- 61 INSERM U1028, CNRS UMR 5292, UCBL1, Lyon, France
- 62 27. Abbottabad University of Science and Technology KP, Pakistan Government College
- 63 University (GCU), Lahore, Pakistan
- 64 28. Genomics England, London, UK.
- 65 29. 3billion inc, Seoul, South Korea
- 66 30. Centogene GmbH, Rostock, Germany
- 67 31. Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston,
- 68 MA 02115, USA
- 69 32. Department of Neurosciences, University of California, San Diego, La Jolla 92093, USA.
- 33. Rady Children's Institute for Genomic Medicine, San Diego 92123, USA
- 71 34. Faculty of Life Sciences, Health Services Academy, Park Road, Islamabad, Pakistan
- 72 35. Department of Biological and Biomedical Sciences, Aga Khan University, Karachi,
- 73 Pakistan
- 74 36. UO Neuroradiologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy
- 75
- ⁷⁶ *These authors contributed equally to this work
- ⁷⁷ [#]Correspondence to:
- 78 Prof. Henry Houlden
- 79 UCL Queen Square Institute of Neurology, Dept. of Neuromuscular Diseases, Queen Square,
- 80 London, UK WC1N 3BG
- 81 E-mail: h.houlden@ucl.ac.uk

82

- 83 Prof. James E.C. Jepson
- 84 UCL Queen Square Institute of Neurology, Dept. of Clinical and Experimental Epilepsy,
- 85 London, UK WC1N 3BG
- 86 E-mail: j.jepson@ucl.ac.uk

87

- 88 **Running title**: *RBL2*-linked neurodevelopmental disorder
- 89 Keywords: RBL2, cell-cycle, neurodevelopmental disorder, Drosophila, Rbf

91 Abstract

92 Retinoblastoma (RB) proteins are highly conserved transcriptional regulators that play important roles during development by regulating cell-cycle gene expression. RBL2 93 94 dysfunction has been linked to a severe neurodevelopmental disorder. However, to date, 95 clinical features have only been described in six individuals carrying five biallelic predicted loss 96 of function (pLOF) variants. To define the phenotypic effects of *RBL2* mutations in detail, we 97 identified and clinically characterized a cohort of 28 patients from 18 families carrying LOF 98 variants in RBL2, including fourteen new variants that substantially broaden the molecular 99 spectrum. The clinical presentation of affected individuals is characterized by a range of 100 neurological and developmental abnormalities. Global developmental delay and intellectual 101 disability were uniformly observed, ranging from moderate to profound and involving lack of 102 acquisition of key motor and speech milestones in most patients. Frequent features included 103 postnatal microcephaly, infantile hypotonia, aggressive behaviour, stereotypic movements 104 and non-specific dysmorphic features. Common neuroimaging features were cerebral atrophy, 105 white matter volume loss, corpus callosum hypoplasia and cerebellar atrophy. In parallel, we 106 used the fruit fly, Drosophila melanogaster, to investigate how disruption of the conserved 107 RBL2 orthologueue Rbf impacts nervous system function and development. We found that 108 Drosophila Rbf LOF mutants recapitulate several features of patients harboring RBL2 variants, 109 including alterations in the head and brain morphology reminiscent of microcephaly, and 110 perturbed locomotor behaviour. Surprisingly, in addition to its known role in controlling tissue 111 growth during development, we find that continued *Rbf* expression is also required in fully 112 differentiated post-mitotic neurons for normal locomotion in Drosophila, and that adult-stage 113 neuronal re-expression of *Rbf* is sufficient to rescue *Rbf* mutant locomotor defects. Taken 114 together, this study provides a clinical and experimental basis to understand genotype-115 phenotype correlations in an RBL2-linked neurodevelopmental disorder and suggests that 116 restoring RBL2 expression through gene therapy approaches may ameliorate aspects of 117 *RBL2* LOF patient symptoms.

118 Introduction

119 Retinoblastoma (RB) proteins play well-defined roles in regulating cell-cycle gene expression 120 during development¹. The mammalian RB family consists of three members, RB1, RBL1 and 121 RBL2, which share overlapping functions and have some exclusive roles as well. RB proteins 122 antagonize the action of E2F transcription factors, which may result in the activation or 123 repression of gene expression depending on the genomic context, and variants of RB proteins 124 are linked to an array of disease states. For example, RB1 is a well-known tumor suppressor, 125 with loss-of-function (LOF) mutations associated with several types of neoplastic lesions including retinoblastoma, prostate cancer, breast cancer, lung cancer and osteosarcoma²⁻⁷. 126 127 RBL1 acts as a tumor suppressor by inhibiting the activity of E2F transcription factors, 128 particularly E2F1, thereby preventing the inappropriate progression of cells through the cell 129 cycle. RBL2 similarly functions as a key regulator of cell division through interactions with 130 E2F4 and E2F5, and promotes senescence by repressing repair genes, controlling DNA 131 methylation, and influencing telomere length⁸⁻¹⁰.

132 RBL1 and RBL2 have also been found to regulate neuronal differentiation and the 133 survival of post-mitotic neurons¹¹. Correspondingly, pathogenic variants in *RBL2* have been 134 associated with severe developmental delay, dysmorphic features, microcephaly, and 135 behavioural abnormalities¹²⁻¹⁴. However, clinical features associated with *RBL2* pathogenic 136 variants have only been characterized in six individuals. Hence, a comprehensive 137 characterization of this disorder has yet to be performed. Furthermore, the cell-types in which 138 *RBL2* expression is required to promote neural development and function remain unclear.

To define the phenotypic effects of *RBL2* mutations in detail, we identified and clinically characterized a cohort of 28 patients from 18 families carrying homozygous or compound heterozygous predicted LOF (pLOF) *RBL2* variants. These studies have expanded the clinical spectrum and identified the most common dysmorphic and neuroradiological features linked to the disorder. Additionally, we have broadened the molecular spectrum by identifying

fourteen new disease-causing variants, providing additional support for *RBL2* LOF as basis ofthis disorder.

RBL2 null mice display embryonic lethality coupled with impaired neurogenesis and 146 147 enhanced apoptosis¹⁵. Therefore, we used the fruit fly, *Drosophila melanogaster*, to 148 investigate how disruption of the conserved RBL2 orthologueue Rbf impacts nervous system 149 function and development. We found that Drosophila Rbf LOF mutants recapitulate several 150 features of patients harboring RBL2 variants, including alterations in the head and brain 151 morphology reminiscent of microcephaly, and perturbed locomotor behaviour. Surprisingly, in 152 addition to its known role in controlling tissue growth during development, we found that 153 continued Rbf expression is also required in fully differentiated post-mitotic neurons for normal 154 locomotion in Drosophila, and that adult-stage neuron-specific re-expression of Rbf is 155 sufficient to rescue Rbf mutant locomotor defects.

156 Collectively, our work provides a clinical and experimental foundation to understand 157 genotype-phenotype linkages in an *RBL2*-linked neurodevelopmental disorder, and suggests 158 that restoring *RBL2* expression in post-mitotic neurons through gene therapy approaches may 159 mitigate some of the morbidities caused by *RBL2* pLOF.

161 Materials and methods

162 Patient identification and genetic investigation

163 **Patient recruitment**

The affected individuals were identified through data sharing with collaborators and screening databases of several diagnostic and research genetic laboratories worldwide, as well as using GeneMatcher¹⁶. Informed consent forms allowing for participation were signed by all study participants and/or their parents or guardians. Genome/exome sequencing (GS/ES) was performed on genomic DNA extracted from blood in different diagnostic or research laboratories worldwide, and if required, candidate variants were confirmed by Sanger sequencing in the available samples from other members of the families.

171

172 Clinical assessment

173 Detailed clinical data and family history were collected for new and reported cases in the form 174 of completing a clinical proforma by the recruiting clinicians. Brain MRIs were reviewed by an 175 experienced pediatric neuroradiologist (M.S.). Video segments of seven patients were suitable 176 for fine analysis of the stereotypies by an experienced neurologist (E.F.). Facial photographs 177 and/or videos were reviewed for 24 patients from 15 families, including 18 new patients from 178 11 families and 6 previously published patients from 4 families¹²⁻¹⁴. Their dysmorphic features 179 were described based on the terminology recommended by Elements of Morphology¹⁷. Where 180 no term was available for a dysmorphic feature seen in a patient, HPO terminology was used 181 instead¹⁸.

182

183 Drosophila studies

184 *Drosophila* husbandry

All stocks and experimental crosses were raised on standard fly-food media and kept at 25 °C with 12 h light: 12 h dark cycles. *Drosophila* strains used in this study are listed in Supplementary Table 1. For behavioural experiments, isogenised lines (indicated in

Supplementary Table 1) were generated by outcrossing each mutation or transgene insertion into the iso31 strain of w^{1118} for five generations¹⁹.

190

191 Immuno-histochemistry

192 Immunohistochemical experiments were performed as previously described²⁰. Briefly, adult or 193 larval brains were dissected in PBS, and fixed in 4% paraformaldehyde (MP biomedicals) for 20 min at room temperature. Tissues were washed with PBST (PBS, 0.3% Triton X-100), 194 195 blocked in 1% goat serum in PBST and incubated in primary antibody overnight at 4 °C. 196 Following primary antibody incubation, tissues were washed a further three times in PBST and 197 incubated overnight in secondary antibody. Antibodies used in this study include mouse anti-Elav (Developmental studies hybridoma bank - Elav-9F8A9)²¹, rabbit anti-cleaved DCP1 (Cell 198 199 signalling technology - #9578), and mouse anti-Repo (Developmental studies hybridoma bank 200 - 8D12)²².

201

202 Drosophila behavioural analyses

203 Drosophila activity was assayed using the Drosophila Activity Monitor system (DAM; Trikinetics, MA, USA) as previously described^{23,24}. Briefly, individual flies obtained between 3-204 205 5 days after eclosing were loaded into glass tubes containing 4% sucrose and 2% agar (w/v) and sealed with cotton-wool plugs. Monitors were kept at 25°C with 12 h light: dark cycles for 206 207 two days to acclimatise. On the third day activity was recorded for 24 h. For measurements of 208 peak activity at ZT0-1 or ZT12-13 (ZT: zeitgeber), activity was taken from the hour after lights 209 on or off during the third day. DAM data was analysed using the Rethomics R package²⁵. Only 210 flies surviving for the full three days were included for analysis. For adult-specific knockdown 211 and rescue experiments, flies were raised at 18°C until 2 days post-eclosion, at which point 212 they were loaded into DAM monitors and moved to 29°C for 3 days (or remained at 18°C for 213 controls).

Larval locomotion assays were conducted by transferring wandering 3rd instar larvae to a large arena containing 2% agar. The arena was placed into a 25°C incubator and larvae were left to acclimatise for 30 s. Larval crawling was video recorded for 1 min. Video files were analysed using ImageJ to calculate total distance travelled.

Negative geotaxis (climbing) assays were conducted as previously described²⁶. Briefly, cohorts of 10 flies were transferred to clean glass measuring cylinders and left to acclimatise for at least 20 mins. Flies were firmly tapped down 3-5 times and number of flies crossing an 8 cm vertical threshold in 12 s was recorded. Three technical replicates were included for each genotype.

223

224 Statistical analyses

225 Statistical data analysis was performed using R or GraphPad Prism. Datasets were first

tested for normality using the Shapiro-Wilk normality test. Statistical analyses were

227 performed using a t-test with Welch's correction or one-way ANOVA with Dunnett's multiple

228 comparisons post-hoc test if data were normally distributed; and Mann-Whitney U-test or

229 Kruskall-Wallace test with Dunn's multiple correction if data were non-normally distributed.

230 **Results**

231 Clinical profile of the study cohort

232 The overall cohort comprises 13 females and 15 males, whose age at last evaluation ranged 233 between 2 and 36 years (median 11, IQR 11). An overview of the clinical findings can be found 234 in Figure 1A and Table 1. Detailed clinical information is available in Supplementary Table 2. 235 Consanguinity was reported in 15 families (83%). Pregnancy and delivery were unremarkable 236 for all the patients for whom information was available (24/24, 100%) and all newborns were 237 at term. Birth parameters of length and weight, when available, were within normal ranges for 238 all the infants, and only one presented with decreased head circumference at birth 239 (HP:0011451). Most of the newborns (26/28, 93%) manifested infantile hypotonia 240 (HP:0008947). Failure to thrive (HP:0001508) and feeding difficulties in the infantile period 241 were documented in 36% and 37% of those examined, respectively (5/14 and 7/19).

242 Global developmental delay (HP:0001263) and intellectual disability (HP:0001249) 243 were reported in all the affected individuals (28/28, 100%). All patients (28/28, 100%) 244 presented motor delay (HP:0001270): while most of the affected children only presented a 245 delay in the achievement of unsupported sitting (21/23 delayed, 2/23 not attained). The 246 majority never attained independent walking (19/27, 70%) and the remainder had delayed 247 acquisition. In the same way, most children (22/27, 81%) showed complete lack of 248 development of speech and expressive language abilities (HP:0001344), while in the 249 remaining individuals (5/27, 19%) development of speech was delayed (HP:0000750) and 250 involved the use of just a few words (Figure 1B). Regression of motor and cognitive abilities 251 (HP:0002376) was reported in three patients (3/22, 14%). When formal cognitive assessment was performed, degree of intellectual disability ranged from moderate (3/27), severe (17/27), 252 253 to profound (7/27) (Figure 1C). Behavioural abnormalities (24/28, 86%) included stereotypies 254 (15/25, 60%), aggressive behaviour (12/15, 80%), autism (6/21, 28%) and, when data were 255 available, sleep disturbance (5/5). Video segments of seven patients were suitable for fine 256 analysis of the stereotypies. The stereotypies usually involved the cervico-facial area (head 257 and/or orofacial region) along with the distal part of the upper limbs, typically in the form of 258 hand clasping/squeezing and mouthing, and finger wringing (Video 1). Seizures occurred in 259 36% of the individuals (10/28). Age of onset of the seizures ranged from 1 to 20 years (median 260 age 8 years, IQR 7). Patients mostly presented a generalized seizure(HP:0002197) (n=6) 261 onset, while focal onset (HP:0007359) occurred in two patients, one with secondary 262 generalization. Seizure types were variable and included tonic-clonic (n=3), myoclonic (n=2), 263 and tonic (n=1). Where EEG was available, abnormalities were documented in 7/10 patients 264 examined (70%), including one patient with no clinical seizures, and included focal, multifocal, 265 and diffuse epileptiform discharges, slowing of background activity and subcortical changes.

Neurological examination showed increased tendon reflexes (HP:0001347) (10/17, 59%), muscle weakness (HP:0001324) (12/22, 55%), axial hypotonia (HP:0008936) (10/21, 47%) and spasticity (HP:0001257) (11/25,44%). Ophthalmological evaluation revealed presence of abnormal findings in half of the cases (14/27, 52%), including strabismus (HP:0000486) (7/19, 37%), nystagmus (HP:0000639) (6/26, 23%), refractive defects (3/25,12%), poor vision (6/26, 23%), optic disc anomalies (4/24, 17%) and orbital mass (2/26, 8%).

At last evaluation, 74% of the patients (20/27) were microcephalic (HP:0000252) (Figure 2A). Dysmorphic features were described in 70% of the cases and included, based on photographic assessment, low anterior hairline (50%), narrow forehead/bifrontal/bitemporal narrowing (83.3%), full or broad nasal tip (77.8%), thick/full lower lip vermilion (66.7%) and broad or tall pointed chin (77.8%) (Figure 2B, Supplementary Table 3).

278

279 Neuroradiological features of *RBL2* patients

Brain MRIs were available for review in 12/28 cases (mean age at MRI 7 years, range 8 months – 17 years). The most frequent neuroimaging finding was a mild-to-moderate cerebral atrophy with antero-posterior gradient and thin corpus callosum (10/12, 83.3%) (Figure 3). Reduced white matter volume with ventricular enlargement was associated in 8/10 cases. In

284 9 subjects (75%), we found white matter signal abnormalities, including faint to marked focal 285 signal changes at the level of forceps minor (8/9), delayed myelination (2/9), and multiple 286 patchy frontal signal changes (1/9). Mild-to-moderate cerebellar atrophy was noted in 7/12 287 individuals (58.3%), with dentate signal changes in 3 cases and clear progression in one 288 subject with a follow-up MRI; in one individual there were also bilateral widespread subcortical 289 signal changes. In 4 other subjects (33%) there was hypoplasia of the inferior portion of the 290 cerebellar hemispheres and/or vermis, with associated foliar anomalies in 1 case. Optic nerve 291 thinning was detected in 5/12 (41%) individuals. Calcifications in the basal ganglia were found 292 in 2/12 (16.6%) cases. Finally, expansile lesions were found in 2 subjects: a large mass 293 extending from the III ventricular floor to the preportine cisterns (hypothalamic hamartoma 294 versus ectopic cerebellar tissue) in P6 and a cystic mandibular lesion in P23 (Supplementary 295 Table 4).

296

297 Molecular spectrum of *RBL2* variants

298 A total of 19 RBL2 variants are included in this study (Figure 4A), 14 of which are newly 299 reported variants not described in the literature. Within the cohort of newly reported families 300 (Figure 3B), only one affected family carried a previously reported variant (c.556C>T, 301 p.Arg186Ter). Molecular findings are shown schematically in Figure 4 and described in detail 302 in Supplementary Table 5. The variants were inherited from unaffected heterozygous parents: 303 23 patients inherited the variant in the homozygous state and 4 in compound heterozygous 304 state. All variants were either absent or found at very low allele frequencies in multiple variant 305 frequency databases (range 0.0-0.00002). The molecular spectrum hereby described includes 306 truncating (n=5), frameshift (n=6) splice (n=6) and large deletions (n=2) (Figure 4C).

According to the American College of Medical Genetics (ACMG) classification, six were classified as pathogenic and thirteen as likely pathogenic. All identified variants were predicted as damaging across a suite of in silico tools and expected to lead to LOF of the

310 protein. Our findings therefore confirm a clear link between biallelic pLOF mutations in *RBL2*

- 311 and a multifaceted neurodevelopmental disorder.
- 312

313 A Drosophila model of RBL2-linked pathology recapitulates morphological patient

314 phenotypes.

315 The Drosophila melanogaster genome encodes two Rb proteins: Rbf and Rbf2. Of these, Rbf 316 shares the greater similarity to RBL2 (39% similarity and 25% identity; compared to 35% 317 similarity and 20% identity for Rbf2). Indeed, fourteen distinct databases of orthology 318 relationships place Rbf as the closest Drosophila orthologue of RBL2, and RBL2 was the 319 closest match for Rbf in а reverse orthology search 320 (https://flybase.org/reports/FBgn0015799#orthologs).

Similar to RBL2, prior work has shown *Drosophila* Rbf interacts with and negatively regulates E2F transcription factor activity to repress cell-cycle gene expression²⁷⁻²⁹. Thus, human RBL2 and *Drosophila* Rbf exhibit functional as well as amino-acid conservation. Published single-cell RNAseq data further indicate that *Rbf* is widely expressed throughout the *Drosophila* nervous system, whereas *Rbf2* is not (Supplementary Fig. 1A, B)³⁰⁻³¹. Hence, we investigated how loss of Rbf function impacted neural development and behaviour in *Drosophila*.

328 We first set out to determine the extent to which Drosophila Rbf loss of function 329 phenotypes resemble *RBL2* patient symptoms. Initially, we examined male and female flies 330 hemizygous or homozygous respectively for a hypomorphic allele of *Rbf* (*Rbf*^{120a}) to determine 331 whether partial loss of Rbf function in flies recapitulated morphological and behavioural phenotypes observed in RBL2 patients. While a previous study suggested that eye 332 morphology in *Rbf^{120a}* hemizygotes was relatively normal³², we noticed that the size of the eye 333 334 was significantly smaller in hemizygous *Rbf*^{120a} males compared to control flies, although the highly organised ommatidial structure appeared unaffected (Figure 5A, B). We also examined 335 the eye-size of female Rbf^{120a} homozygotes and females trans-heterozygote for Rbf^{120a} and 336

the *Rbf*¹⁴ null allele (note that adult *Rbf*¹⁴ homozygotes are embryonic lethal)³³. Both *Rbf*^{120a} homozygote and *Rbf*^{120a}/*Rbf*¹⁴ trans-heterozygous females also displayed smaller eyes compared to wild-type control and *Rbf*^{120a}/+ or *Rbf*¹⁴/+ heterozygote flies (Figure 5C).

Since microcephaly is a clinical feature of *RBL2* patients, we next examined whether brain size was also reduced in *Drosophila Rbf* mutants (Figure 5D-G). While overall brain size was not significantly smaller in *Rbf*^{120a} hemizygote males (Figure 5E), we observed a significant reduction in the size of *Rbf*^{120a} hemizygote optic lobes, visual processing centres that contain > 60% of all neurons in the fly brain³⁴ (Figure 5F). In contrast, the central brain region of *Rbf*^{120a} hemizygotes was unaltered (Figure 5G).

Rb proteins have been linked to apoptosis in human³⁵ and Drosophila³⁶, with Rbf^{120a} 346 347 mutants displaying increased apoptosis in the eye imaginal disc (the developmental precursor 348 to the adult eye^{32}). We therefore reasoned that decreased brain size in *Rbf* mutants might be 349 driven by an increase in cell death. To determine the amount of apoptosis in the brains of *Rbf*^{120a} mutants, we stained tissues with anti-DCP1, which recognises the cleaved version of 350 a caspase protein involved in apoptotic cell death. Examination of adult Rbf^{120a} brains 351 352 indicated minimal apoptosis, as was similarly observed in control adult brains (Figure 5H). 353 However, examination of larval brains, in which most neurons are in a more immature state, revealed significantly greater numbers of apoptotic cells in *Rbf*^{120a} mutants than controls 354 355 (Figure 5I, J). This suggests that neuronal precursors and immature neurons are more 356 sensitive to the induction of apoptosis when Rbf is depleted, in agreement with previous 357 observations of the developing eye³². Overall, the morphological phenotypes we observe in 358 the adult head and brain are consistent with the microcephaly seen in RBL2 patients, 359 indicating a conserved function for the RBL2 and Rbf proteins in controlling head morphology 360 during development.

361

362 Drosophila Rbf mutants display locomotor defects.

363 Since profound motor delay was observed in all patients homozygous for RBL2 variants, we 364 also tested whether Drosophila Rbf mutants exhibited motor defects. To do so, we utilised the Drosophila Activity Monitor (DAM) system²³, which quantifies spontaneous activity by 365 recording the number of times individual flies interrupt an infra-red beam bisecting a glass tube 366 housing each fly (Figure 6A). Rbf^{120a} hemizygotes showed significantly lower locomotor activity 367 compared to controls both over a 12 h light: 12 h dark period (Figure 6B) and during a one-368 369 hour window following lights-on (ZT0-1; ZT – zeitgeber time) that corresponds to a period of peak activity (Figure 6C). We observed a similar effect in female Rbf^{120a} homozygotes and 370 *Rbf*^{120a}/*Rbf*¹⁴ trans-heterozygotes, but not in females that are heterozygous for either allele 371 372 (Figure 6D), thus confirming that the above alterations in locomotor activity were caused by 373 mutations in Rbf. To further characterise these behavioural abnormalities, we conducted negative geotaxis (climbing) assays²⁶. *Rbf*^{120a} hemizygote males displayed significantly lower 374 375 climbing ability compared to control animals (Supplementary Figure 1C, D), further indicating 376 that Rbf LOF induces significant motor defects in flies. Thus, Drosophila Rbf mutants 377 recapitulate morphological and behavioural phenotypes observed in patients harbouring RBL2 378 mutations.

379

380 *Rbf* is highly expressed in adult neurons.

381 Given the strong phenotypic similarities between humans and fruit flies harbouring RBL2/Rbf 382 LOF mutations, we tested whether we could utilise *Drosophila* to probe the mechanistic basis 383 of RBL2-linked neurodevelopmental defects. Rb proteins are well-known for their role in 384 transcriptional repression of cell-cycle related genes at the G1/S phase transition³⁷. Hence, it 385 is expected that *Rbf* would be expressed in the developing brain. However, it is unclear whether Rbf also continues to play a role in fully differentiated neurons following cell-cycle 386 387 exit. To investigate which cells in the nervous system express Rbf, we took advantage of a 388 CRISPR-mediated insertion of a Gal4 cassette (CRIMIC insertion) in an Rbf intron, which 389 results in expression of Gal4 under control of Rbf regulatory sequences (termed Rbf-Gal4

390 hereafter)³⁸ (Figure 6E). Crossing these flies to a UAS-mCherry-nls line yields expression of 391 nuclear mCherry as a reporter of *Rbf* expression. Examination of *Rbf*-Gal4 activity in larval 392 brains revealed widespread expression, indicating that *Rbf* is indeed broadly expressed in the 393 developing brain (Supplementary Figure 1E). More surprisingly, adult brains – which do not 394 display appreciable neurogenesis under normal conditions - also exhibited widespread Rbf-395 driven mCherry expression that co-localised with the neuronal marker Elav (Figure 6F and 396 Supplementary Figure 1F). Hence, Rbf expression persists in neurons long after terminal cell-397 cycle exit. In contrast, only a small population of Repo-labelled glial cells expressed mCherry 398 under the control of *Rbf*-Gal4 (Figure 6F). These findings are consistent with published single-399 cell RNAseq data showing that *Rbf* is preferentially expressed in post-mitotic neurons relative 400 to glia (Supplemental Figure 1A).

401

402 **Rbf knockdown in neurons causes severe behavioural defects.**

403 To directly test for an underappreciated role of Rbf in fully differentiated post-mitotic cells, we 404 examined whether reducing Rbf expression in post-mitotic neurons resulted in locomotor 405 defects similar to those observed in constitutive Rbf hypomorph flies. To do so, we used 406 transgenic RNAi to deplete *Rbf* specifically in fully differentiated neurons using the *nSyb*-Gal4 407 driver. Strikingly, using the DAM system once more, we found that pan-neuronal knockdown of *Rbf* with a previously verified shRNA-expressing line³⁹ severely reduced peak movement in 408 409 adult flies (Figure 6G). To rule out off-target effects, we repeated these experiments using two 410 additional RNAi lines targeting Rbf mRNA. Both constructs similarly reduced peak movement when expressed in post-mitotic neurons (Supplementary Figure 2A, B). In contrast to neuronal 411 412 knockdowns, RNAi-mediated depletion of *Rbf* in glial cells did not significantly reduce peak 413 locomotor activity (Figure 6H), in accordance with the above observation that *Rbf* expression 414 is less abundant in glia than neurons (Figure 6F).

415 We next used climbing assays to quantify stimulus-induced negative geotaxis. These 416 assays further indicated that flies with reduced Rbf expression in neurons have severe motor

417 defects, showing significantly reduced climbing ability compared to controls (Supplementary 418 Figure 2C). Interestingly, larval locomotion was unchanged in either *Rbf* hypomorphs or 419 following knockdown of *Rbf* in post-mitotic neurons, suggesting that larval neuronal lineages 420 have a differential requirement for Rbf compared to their adult counterparts (Supplementary 421 Figure 2D, E). Importantly, *Rbf* knockdown in adult post-mitotic neurons did not reduce optic 422 lobe size nor induce a measurable increase in neuronal apoptosis (Supplementary Figure 2F, 423 G). Taken together, these data suggest that *Rbf* plays important neuron-autonomous roles 424 that are essential for adult locomotor behaviour and which are independent of neuronal 425 viability.

426

427 Multiple neuronal subtypes are affected by Rbf knockdown.

428 To identify which cell-types in the post-mitotic brain are affected by *Rbf* knockdown, we used 429 specific drivers to restrict *Rbf* shRNA expression to genetically defined subsets of neurons. 430 We knocked down *Rbf* in discrete neuronal subtypes, including cholinergic, GABAergic, and 431 glutamatergic neurons. Of these, Rbf knockdown in glutamatergic neurons (which include 432 Drosophila motoneurons) yielded the most significant decline in locomotor activity, as 433 measured using the DAM system (Figure 6I and Supplementary Figure 3). Rbf knockdown in 434 GABAergic and cholinergic neurons did not significantly decrease overall activity across 24 h 435 (Supplementary Figure 3). However, in the one-hour period following lights-on (ZT0-1), during 436 which control flies exhibit a peak period of locomotor activity, both cholinergic and GABAergic 437 Rbf knockdown flies showed significantly reduced activity (Figure 6I), indicating a partial 438 perturbation of locomotor capacity. We further tested the motor defect of these flies by 439 conducting climbing assays. These experiments confirmed that reduced Rbf expression in 440 glutamatergic, cholinergic, or GABAergic neurons, resulted in significantly decreased climbing 441 ability compared to controls (Supplementary Figure 2C). In contrast, Rbf knockdown in 442 peptidergic neurons did not perturb overall or peak locomotor activity (Figure 6I and 443 Supplementary Figure 3). These data demonstrate that Rbf acts in several post-mitotic

444 neuronal subtypes to modulate movement, with glutamatergic neurons representing a445 particularly relevant cellular locus.

446

447 **Post-mitotic restoration of Rbf rescues locomotor defects in** *Rbf* **hypomorphs.**

448 Since *Rbf* mutants display morphological phenotypes consistent with cell-cycle defects and 449 apoptosis during development, but also behavioural abnormalities that can be induced by 450 knockdown of *Rbf* in post-mitotic neurons, we questioned whether locomotor phenotypes in 451 constitutive *Rbf* hypomorphs were due to developmental defects or reduced *Rbf* expression 452 post-neurogenesis (i.e. in post-mitotic neurons). To address this question, we expressed Rbf 453 solely in fully differentiated neurons in the *Rbf* hypomorph background. Interestingly, this manipulation fully rescued the reduced peak activity of Rbf^{120a} hypomorphs, while over-454 455 expression of *Rbf* in a wild-type background had no effect on peak locomotor activity (Figure 456 7A).

457 To more precisely interrogate whether Rbf LOF affects adult behaviour due to 458 developmental perturbations or cell-autonomous activity in adult neurons, we performed 459 complementary adult-stage neuron-specific knockdown and rescue experiments. To do so we 460 utilised *tub*-Gal80^{ts}, a globally expressed temperature-sensitive inhibitor of Gal4-mediated 461 transgene expression⁴⁰. In concert with the *nsyb*-Gal4 driver and *Rbf* shRNA or transgenes, 462 this construct allowed us to examine the effects of both adult neuron-specific *Rbf* knockdown 463 in an otherwise wild-type background (Figure 7B, C), and adult neuron-specific re-expression 464 of Rbf in an *Rbf* hypomorph background (Figure 7B, D). We first found that, as expected, peak 465 locomotion in wild-type flies did not significantly differ from controls when Rbf shRNA 466 expression in post-mitotic neurons was constitutively repressed at 22°C by active Gal80^{ts} 467 (Figure 7B, Ci). In contrast, inducing adult-stage neuronal knockdown of *Rbf* by shifting mature 468 experimental flies to 29°C (Gal80 inactive, *Rbf* shRNA expressed) significantly reduced peak 469 locomotion compared to control flies expressing an irrelevant shRNA (Figure 7B, Cii).

470 In the converse experiment, *Rbf* hypomorphs expressing transgenic Rbf in post-mitotic 471 neurons (Rbf^{120} , nsyb > Rbf) showed significantly higher peak locomotion at 22°C compared 472 to flies of the same genotype but harbouring the repressive *tub*-Gal80^{ts} construct (Figure 7B, 473 Di; Gal80 active, transgenic Rbf not expressed). However, when flies were raised at 22°C and 474 then moved to a permissive temperature of 29°C at the adult stage (Figure 7B, Dii; Gal80 475 inactive, Rbf expressed), we observed no difference in peak activity between these two 476 genotypes, suggesting that adult-specific restoration of Rbf expression in post-mitotic neurons 477 was sufficient to rescue locomotor defects in *Rbf* hypomorphs. By extension, these findings 478 suggest that defects in post-mitotic neuronal function may contribute to morbidities in RBL2 479 patients, particularly those associated with motor dysfunction.

481 **Discussion**

482 The findings presented in this study shed light on a rare recessive neurodevelopmental 483 disorder associated with mutations in the RBL2. Alongside the other RB family members (RB1 484 and RBL1), RBL2 acts as a crucial transcriptional regulator, particularly influencing neuronal 485 differentiation and the survival of post-mitotic neurons. Unlike RB1 and RBL1, RBL2 is 486 uniquely associated with a neurodevelopmental phenotype, however, only six individuals have been documented so far¹²⁻¹⁴. The limited number of patients, along with the isolated nature of 487 488 the reports without comparative analysis, restricted the possibility of defining the phenotypic 489 and genotypic spectrum of this disorder.

490 To address this gap, we have identified and clinically characterized a cohort of twenty-491 eight patients from eighteen families carrying homozygous or compound heterozygous 492 predicted loss of function variants in RBL2. Within this cohort, we identified fourteen novel 493 variants, bringing the total count of disease-associated pathogenic variants to nineteen. All 494 variants are predicted to cause LOF, suggesting that the disease phenotype is primarily 495 caused by total loss of protein function rather than alteration of defined active sites or protein 496 interactions. However, it is essential to acknowledge potential limitations, such as the 497 possibility of missing rare novel missense variants in specific domains that could be associated 498 with milder forms of the disease.

499 The clinical presentation of affected individuals is characterized by a range of 500 neurological and developmental abnormalities. Notably, global developmental delay, and 501 intellectual disability were uniformly observed in the cohort. Interestingly, most of the patients 502 lacked acquisition of key milestones, like walking and speech development, highlighting the 503 disease severity from very early stages of the disorder. Postnatal microcephaly was observed 504 in a considerable proportion of patients, while head circumference was normal in almost all 505 the patients at birth, suggesting a progressive disorder. Remarkably, the vast majority of 506 patients presented stereotypies, variably associated with autism spectrum disorder (ASD) and

aggressive behaviour. Whilst the present cohort of patients did have facial dysmorphism, ouranalysis did not suggest a recognizable facial 'gestalt'.

509 Common neuroimaging features included cerebral atrophy with an antero-posterior 510 gradient variably associated with white matter volume loss and corpus callosum hypoplasia. 511 In addition, cerebellar atrophy was noted in the majority of *RBL2* patients. Considering the 512 presence of postnatal microcephaly in most cases, these findings suggest that 513 neurodegeneration is an important feature of this disorder. As further confirmation, we also 514 noted in most cases bilateral faint-to-marked signal changes at the level of the forceps minor, 515 in keeping with an "ear-of-the-lynx" sign. This neuroimaging feature has been reported in hereditary spastic paraplegias (SPG7, 11 and 15)^{41,42} and other neurodegenerative disorders, 516 including those related to variants in the LNPK, CAPN1, and ATP13A243-45. Indeed, a 517 518 neurodegenerative component is consistent with our Drosophila data, which suggest that the 519 decreased brain size observed in *Rbf* hypomorphs is driven by an increase in cell death, most 520 likely arising from cell-cycle defects in neuronal precursors and immature neurons.

521 Additionally, a total of three affected individuals were found to have expansile lesions: 522 one orbital mass, one cystic mandibular lesion, and a large mass extending from the III 523 ventricular floor to the prepontine cisterns. This is in line with previous studies that pointed to 524 the potential role of RBL2 dysfunction in the evolution of cancer⁴⁶ and confirms the dual role 525 of RBL2 in both tumor suppression and neuronal differentiation and survival, thus providing 526 further connection between tumorigenic processes and neurodevelopmental disorders⁴⁷. 527 Overall, both the clinical and neuroradiological findings underscored substantial intrafamilial 528 and interfamilial variations in phenotypic expressions and severity, revealing considerable 529 complexity within and between families.

530 To investigate the mechanisms linking RBL2 to neuronal development and function, 531 we turned to the fruit fly, *Drosophila melanogaster*. Reductions in eye and optic lobe size, in 532 *Drosophila Rbf* mutants are analogous to the microcephaly, brain atrophy and optic nerve 533 hypoplasia seen in *RBL2* patients. Furthermore, the presence of apoptotic cells in the

534 *Drosophila* developing brain is consistent with these phenotypes and points towards a model 535 in which cell death during development leads to the atrophy observed in patient brains. The 536 movement phenotypes we observe in mutant animals also seem to recapitulate aspects of the 537 patient symptoms (e.g. gait abnormalities).

538 The similarities between Drosophila and patient phenotypes, coupled with the 539 conserved sequence and molecular interactors of Rbf, support the use of Drosophila Rbf 540 mutants as a model to understand the patho-mechanisms underlying *RBL2*-linked disorders 541 and mammalian neural Rb function more broadly. Indeed, we uncovered an unexpected 542 movement-promoting role for Drosophila Rbf in adult post-mitotic neurons. How Rbf influences 543 gene expression in post-mitotic neurons is unclear. In some post mitotic cells, Rbf has been 544 shown to modulate gene expression outside of its canonical function in repressing cell-cycle 545 genes (for example in controlling muscle differentiation)⁴⁸. Therefore, it is conceivable that Rbf 546 also coordinates undefined gene expression programmes in mature neurons. Alternatively, 547 Rbf neuronal-knockdown phenotypes may arise from the canonical action of Rbf on cell-cycle 548 gene promoters - for example, in sustaining the epigenetic environment that maintains cell-549 cycle gene repression. Defining how Rbf and RBL2 influence gene regulatory networks in the 550 mature fly and mammalian nervous system will thus be productive lines of future enquiry.

551 Our Drosophila studies advocate a model in which Rbf – and by extension RBL2 – acts 552 sequentially in neural precursors and post-mitotic neurons to promote normal brain 553 morphology and locomotor activity respectively (Figure 7E). Taken together, our work provides 554 a clinical and experimental foundation to understand genotype-phenotype linkages in an 555 RBL2-linked neurodevelopmental disorder and suggests that restoring RBL2 expression 556 through gene therapy approaches may mitigate some of the multifaceted morbidities caused 557 by *RBL2* pLOF. While our study illustrates parallels between human and fly Rb protein function 558 in the nervous system, it is possible that some divergence in function has occurred between 559 the two species. The human genome contains three Rb genes and eight genes encoding interacting E2F transcription factors⁴⁹. Therefore, the greater complexity of the RB/E2F 560

- 561 network in humans could result in altered biological outcomes. However, the similarities
- 562 observed between RBL2 patient phenotypes and *Drosophila Rbf* mutant phenotypes indicates
- 563 that RBL2/Rbf protein function in the CNS is likely to be conserved across metazoan species.
- 564 Future studies in *Drosophila* may thus yield further insights into the mechanisms underlying
- 565 *RBL2* pathology and inform therapeutic directions.
- 566
- 567
- 568

569 **Data availability**

- 570 The authors declare that the data supporting the findings of this study are available within the
- 571 paper and its supplementary information files.
- 572

573 Acknowledgements

- 574 We would like to thank the patients and the families for their participation in this study. We
- 575 would like to thank members of the Jepson and Houlden groups for their feedback and support
- 576 on this project. We also thank Diego Sainz de La Maza and the Amoyel lab (University College
- 577 London) for fly stocks and helpful advice.
- 578

579 **Funding**

- 580 This study was supported by the Wellcome Trust (WT093205MA and WT104033AIA to H.H.),
- 581 Medical Research Council (H.H.), European Community's Seventh Framework Programme
- 582 (FP7/2007-2013, under grant agreement No. 2012-305121 to H.H.), the National Institute for
- 583 Health Research (NIHR), University College London Hospitals, Biomedical Research Centre,
- and Fidelity Foundation. This work was also funded by MRC Senior Non-Clinical Fellowship
- 585 (MR/V03118X/1) to J.E.C.J. WKC was funded by P50HD109879.

586

587 **Competing interests**

588 C.B. is an employee of Centogene. G.H.S is an employee of 3billion. L.M. has received 589 personal fees for ad hoc consultancy from Mendelian Ltd, a rare disease digital healthcare 590 company. The remaining authors report no competing interests.

591

592 Ethical declarations

Individuals and/or their legal guardians recruited for this study gave informed consent for their
 participation. This study received approval from the Review Boards and Bioethics Committees
 at University College London Hospital (project 06/N076). Permission for inclusion of their

- anonymized medical data in this cohort, including photographs, was obtained using standard
- 597 forms at each local site by the responsible referring physicians.

598

- 600
- 601
- 602

603 Figure legends.

604 Figure 1. RBL2-related disorder is characterized by a range of neurological, behavioural 605 and developmental abnormalities. A. Representation of the most frequent clinical features 606 observed in the RBL2 patients (Y axis: clinical features, X axis: number of patients). B. 607 Timeline-style schematic outlining the acquisition of key developmental milestones observed 608 in the affected individuals. Most of the individuals did not attain independent sitting, walking or 609 speech development (blue bar indicates range at last evaluation), while the others presented 610 delayed acquisition (orange, line indicates median age). Normal range is indicated in green. 611 **C.** Schematic depiction of the degree of intellectual disability observed in the patients (number 612 of patients indicated in bottom line). The spectrum ranged from moderate (left) to profound 613 (right).

614

Figure 2. *RBL2* patients present postnatal microcephaly and dysmorphic features, without a recognizable facial 'gestalt'. A. Schematic representation of head circumference measurements, expressed in standard deviations (SD). Head circumference was within normal ranges at birth, while reduced at last examination (left panel). The right panel illustrates age at last follow-up and measurements in SD. **B.** Facial features of the patients.

620

621 Figure 3. Molecular spectrum of loss-of-function variants in *RBL2*. A. Schematic

622 representation of variants location on the *RBL2* gene. Upper part: newly reported variants.

623 Lower part: previously reported variants. **B.** Pedigrees of the newly reported patients. Solid

black, affected. Genotype, where indicated, represent results of segregation. C.

625 Classification of variants according to type.

626

Figure 4. Neuroimaging features of RBL2-related disorder. Sagittal T1-weighted image
 (first image), axial T2-weighted or FLAIR image (central image), coronal T1 or T2-weighted or
 FLAIR image (last image). Most subjects have an enlargement of the cerebral CSF spaces

with an antero-posterior gradient associated with thinning of the corpus callosum, particularly
in the anterior portions. There is additional cerebellar atrophy in P10, P12, P20, P22, and P23.
Bilateral mild-to-moderate signal changes are noted at the level of the forceps minor in P6,
P19, P20, P21, P22, and P23. Note the large prepontine lesion in P10.

634

Figure 5. Loss of Rbf activity reduces neuronal growth in Drosophila. A. Representative 635 images of adult eyes in control (iso31) and Rbf^{120a} hypomorphs. Scale bars = 0.3 mm. **B**. 636 Quantification of eye sizes in male Rbf^{120a} hemizygotes (n = 16) compared to controls (n = 9). 637 638 **C.** Quantification of eye sizes in female *Rbf* allelic combinations (n = 5-8). **D**. Representative images of adult brains in control and Rbf^{120a} adult males. Scale bars = 50 µm. E-G. 639 Measurements of brain morphology in control and Rbf^{120a} hemizygotes adult males (n = 10 640 641 brains. 10 central brains, and 20 optic lobes, per genotype). H. Quantification of apoptotic (DCP1 positive) cells in control and Rbf^{120a} hemizygotes adult male brains (n = 6 per 642 genotype). I. Representative images of DCP1-labled control (n = 9) and Rbf^{120a} hemizygote 643 644 (n = 6) third instar larval nervous system. Nuclei are counterstained with DAPI. Scale bars = 645 20 µm. J. Quantification of apoptosis in control and *Rbf*^{120a} hemizygotes third instar larval 646 brains. Error bars: SEM. * p< 0.05, ** p<0.005, *** p< 0.0005, ns - p> 0.05, unpaired t-test 647 with Welch's correction (B, E, F), one-way ANOVA with Dunnett post-doc test (C), Mann-648 Whitney U-test (G, H, J).

649

Figure 6. Rbf acts in post-mitotic neurons to promote movement in *Drosophila*. A. Schematic representation of the *Drosophila* Activity Monitor (DAM) system. B-C. DAM activity in *Rbf*^{120a} hemizygotes (n = 38) and controls (iso31; n = 31) across a 24 h period (B) or during zeitgeber time (ZT) 0-1, a period of peak activity (C). D. DAM activity in adult females harbouring trans-heterozygote or heterozygote *Rbf* allelic combinations, and wild type iso31 controls during ZT0-1. n = 16-20. E. Schematic representation of the CRIMIC insertion in the *Rbf* locus, which allows for *Rbf*-dependent Gal4 reporter expression. F. *Rbf*-Gal4 driven

657 nuclear mCherry expression in the adult central brain. Neurons and glia are counterstained 658 with antibodies against ELAV and REPO respectively. Scale bar = $20 \mu m$. G. Pan-neuronal 659 post-mitotic knockdown of *Rbf* severely reduces peak locomotor activity during ZT0-1. n = 20-54. H. Knockdown of Rbf in glial cells (using repo-Gal4 to express Rbf shRNA) does not 660 significantly reduce peak locomotor activity during ZT0-1 compared to both driver and 661 transgene alone controls (n = 18-24). I. Knockdown of *Rbf* in cholinergic, glutamatergic, and 662 663 GABAergic neurons, reduces peak activity during ZT0-1 in adult males. n = 11-41. Upper 664 significance notation is relative to *Rbf* shRNA alone controls, lower significance notation is relative to Gal4 driver alone controls. Error bars: SEM. * p< 0.05, ** p<0.005, *** p< 0.0005, 665 666 ns – p> 0.05, unpaired t-test with Welch's correction (B), Mann-Whitney U-test (C), one-way 667 ANOVA with Dunnett post-doc test (D, H, I), or Kruskal-Wallis test with Dunn's post-hoc test 668 (G).

669

670 Figure 7. Adult-stage neuronal expression of Rbf rescues locomotor defects in Rbf 671 hypomorphs. A. Effects of post-mitotic, neuron-specific *Rbf* expression on peak locomotor 672 activity in either wild-type or Rbf^{120a} hypomorph backgrounds. Data are from adult males. n = 673 15-21. B. Experimental paradigm for temperature-induced knockdown and rescue 674 experiments shown in panels C and D. C. Quantification of peak activity for control adult male 675 flies kept at (i) non-permissive temperature: mCherry (n = 33) or Rbf (n = 23) shRNA 676 expression - repressed; and (ii) experimental adult male flies maintained at a permissive 677 temperature: mCherry (n = 24) or Rbf (n = 16) shRNA expression – permitted. D. (i) 678 Constitutive suppression of neuronal RBF expression via *tub*-Gal80^{ts} significantly decreases peak locomotor activity in Rbf^{120a} ; nsyb > Rbf adult males. Rbf^{120a} , nsyb > Rbf: n = 13; Rbf^{120a} , 679 680 *tub*-Gal80^{ts}, *nsyb* > *Rbf*: n = 10. (ii) Peak activity in adult male flies that robust RBF expression solely permitted in adult-stage post-mitotic neurons is not significantly different from Rbf^{120a} 681 682 hypomorphs with constitutive post-mitotic neuronal expression of RBF. Rbf^{120a} , nsyb > Rbf. n = 15; Rbf^{120a} , tub-Gal80^{ts}, nsyb > Rbf. n = 13. **E.** Model of dynamic changes in RBF function 683

- 684 in developing and adult neurons. Error bars: SEM. * p< 0.05, ** p<0.005, *** p< 0.0005, ns -
- 685 p> 0.05, Kruskal-Wallis test with Dunn's post-hoc test (A), unpaired t-test with Welch's
- 686 correction (Ci, Cii, Di, Dii).

688 Supplementary Figure 1. A-B. Single-cell RNAseq-derived t-distributed stochastic neighbor 689 embedding (t-SNE) plots showing Rbf (A) and Rbf2 (B) expression, alongside markers for glial 690 cells (repo) and post-mitotic neurons (nsyb), in the adult fly brain. Gene expression across 691 adult brain cells is illustrated using SCope [1]. C. Schematic showing protocol to assess 692 climbing ability in adult flies. **D.** Number of flies (out of n = 10) passing a given threshold (see 693 Materials and Methods) as a measure of climbing ability. Control adult males: n = 5 replicates, *Rbf*^{120a} hemizygotes: n = 6 replicates. Error bars: SEM. ** p<0.005, unpaired t-test with Welch's 694 695 correction. E-F. Rbf-Gal4 driven nuclear mCherry expression in the Drosophila larval (E) and 696 adult (F) brain. Adult neuronal nuclei are counterstained with an antibody against ELAV in (F). 697 Scale bar = $100 \,\mu m$.

698

699 Supplementary Figure 2. A-B. Expression in post-mitotic neurons of two distinct shRNAs 700 (denoted as 330256 (A) and 65929 (B)) targeting Rbf mRNA reduces peak activity in adult 701 Drosophila males. A: n = 20-37. B: n = 27-35. C. Number of flies (out of n = 10) passing a 702 given threshold as a measure of climbing ability. n = 6-20 replicates. **D-E.** Crawling ability in 703 control or *Rbf^{120a}* hypomorph 3rd instar larvae (D) or larvae subject to *Rbf* knockdown in post-704 mitotic neurons versus driver/transgene alone controls (E). D: n = 10 per genotype. E: n = 6-705 9. F-G. Mean optic lobe size (F) and number of apoptotic (DCP1-positive) cells in adult male 706 brains subject to Rbf knockdown in post-mitotic neurons versus driver/transgene alone 707 controls. F: n = 8-14. G: n = 5-7. Error bars: SEM. * p< 0.05, ** p< 0.005, *** p< 0.0005, ns -708 p> 0.05, one-way ANOVA with Dunnett post-doc test (A, B, G), Kruskal-Wallis test with Dunn's 709 post-hoc test (C, E, F), or unpaired t-test with Welch's correction (D).

710

711 **Supplementary Figure 3.**

Knockdown of *Rbf* in glutamatergic neurons, reduces total activity during ZT0-24 in adult
 males. n = 11-41. Upper significance notation is relative to *Rbf* shRNA alone controls, lower

714	significance notation is relative to Gal4 driver alone controls. Error bars: SEM. * p< 0.05, **
715	p<0.005, *** p< 0.0005, ns – p> 0.05, Kruskal-Wallis test with Dunn's post-hoc test.

717 Video legend

Video illustrating the stereotypies observed in patients with a neurodevelopmental encephalopathy due to biallelic *RBL2* pathogenic variants. Segment 1 (patient from family F3) shows orofacial stereotypies with teeth grinding associated with hand clasping stereotypies. Segment 2 (from family F11) shows multiple hands stereotypies comprising hand squeezing, hand mouthing, finger wiggling and finger tapping, and multiple orofacial stereotypies with a prominent involvement of the tongue.

731 References

Harbour JW, Dean DC. Rb function in cell-cycle regulation and apoptosis. Nat Cell
 Biol. 2000;2(4):E65-E67. doi:10.1038/35008695

2. Yao Y, Gu X, Xu X, Ge S, Jia R. Novel insights into RB1 mutation. Cancer Lett.

735 2022;547:215870. doi:10.1016/j.canlet.2022.215870

736 3. Chai P, Luo Y, Yu J, et al. Clinical characteristics and germline mutation spectrum of

737 RB1 in Chinese patients with retinoblastoma: A dual-center study of 145 patients. Exp Eye

738 Res. 2021;205:108456. doi:10.1016/j.exer.2021.108456

Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the retinoblastoma
gene in osteosarcomas. Cancer Res. 1994;54(11):3042-3048.

5. Berge EO, Knappskog S, Geisler S, et al. Identification and characterization of
retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Mol Cancer.
2010;9:173. Published 2010 Jul 1. doi:10.1186/1476-4598-9-173

6. Sharma A, Yeow WS, Ertel A, et al. The retinoblastoma tumor suppressor controls
androgen signaling and human prostate cancer progression. J Clin Invest.
2010;120(12):4478-4492. doi:10.1172/JCI44239

747 7. Niederst MJ, Sequist LV, Poirier JT, et al. RB loss in resistant EGFR mutant lung
748 adenocarcinomas that transform to small-cell lung cancer. Nat Commun. 2015;6:6377.
749 Published 2015 Mar 11. doi:10.1038/ncomms7377

8. Hijmans EM, Voorhoeve PM, Beijersbergen RL, van 't Veer LJ, Bernards R. E2F-5, a
new E2F family member that interacts with p130 in vivo. Mol Cell Biol. 1995;15(6):3082-3089.
doi:10.1128/MCB.15.6.3082

Fiorentino FP, Symonds CE, Macaluso M, Giordano A. Senescence and p130/Rbl2: a
new beginning to the end. Cell Res. 2009;19(9):1044-1051. doi:10.1038/cr.2009.96

10. Kong LJ, Meloni AR, Nevins JR. The Rb-related p130 protein controls telomere
lengthening through an interaction with a Rad50-interacting protein, RINT-1. Mol Cell.
2006;22(1):63-71. doi:10.1016/j.molcel.2006.02.016

Liu DX, Nath N, Chellappan SP, Greene LA. Regulation of neuron survival and death
by p130 and associated chromatin modifiers. Genes Dev. 2005;19(6):719-732.
doi:10.1101/gad.1296405

12. Brunet T, Radivojkov-Blagojevic M, Lichtner P, Kraus V, Meitinger T, Wagner M.
Biallelic loss-of-function variants in RBL2 in siblings with a neurodevelopmental disorder. Ann
Clin Transl Neurol. 2020;7(3):390-396. doi:10.1002/acn3.50992

- Samra N, Toubiana S, Yttervik H, et al. RBL2 bi-allelic truncating variants cause severe
 motor and cognitive impairment without evidence for abnormalities in DNA methylation or
 telomeric function. J Hum Genet. 2021;66(11):1101-1112. doi:10.1038/s10038-021-00931-z
- Rips J, Abu-Libdeh B, Koplewitz BZ, et al. Orbital nodular fasciitis in child with biallelic
 germline RBL2 variant. Eur J Med Genet. 2022;65(6):104513.
 doi:10.1016/j.ejmg.2022.104513
- 15. LeCouter JE, Kablar B, Hardy WR, et al. Strain-dependent myeloid hyperplasia, growth

deficiency, and accelerated cell cycle in mice lacking the Rb-related p107 gene. Mol Cell Biol.

772 1998;18(12):7455-7465. doi:10.1128/MCB.18.12.7455

16. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for
connecting investigators with an interest in the same gene. Hum Mutat. 2015;36(10):928-930.
doi:10.1002/humu.22844

Allanson JE, Cunniff C, Hoyme HE, McGaughran J, Muenke M, Neri G. Elements of
morphology: standard terminology for the head and face. Am J Med Genet A. 2009;149A(1):628. doi:10.1002/ajmg.a.32612

779 18. Robinson PN, Mundlos S. The human phenotype ontology. Clin Genet.
780 2010;77(6):525-534. doi:10.1111/j.1399-0004.2010.01436.x

19. Ryder E, Blows F, Ashburner M, et al. The DrosDel collection: a set of P-element
insertions for generating custom chromosomal aberrations in Drosophila melanogaster.
Genetics. 2004;167(2):797-813. doi:10.1534/genetics.104.026658

784 20. Simon A. Lowe, Abigail D. Wilson, Gabriel Aughey, Animesh Banarjee, Talya Goble, 785 Nell Simon-Batsford, Angelina Sanderson, Patrick Kratschmer, Maryam Balogun, Hao Gao, 786 Sherry S. Aw, James E.C. Jepson, bioRxiv 2023.09.20.558625; doi: 787 10.1101/2023.09.20.558625

O'Neill EM, Rebay I, Tjian R, Rubin GM. The activities of two Ets-related transcription
factors required for Drosophila eye development are modulated by the Ras/MAPK pathway.
Cell. 1994;78(1):137-147. doi:10.1016/0092-8674(94)90580-0

Alfonso TB, Jones BW. gcm2 promotes glial cell differentiation and is required with
glial cells missing for macrophage development in Drosophila. Dev Biol. 2002;248(2):369-383.
doi:10.1006/dbio.2002.0740

Pfeiffenberger C, Lear BC, Keegan KP, Allada R. Locomotor activity level monitoring
using the Drosophila Activity Monitoring (DAM) System. Cold Spring Harb Protoc.
2010;2010(11):pdb.prot5518. Published 2010 Nov 1. doi:10.1101/pdb.prot5518

Kratschmer P, Lowe SA, Buhl E, et al. Impaired Pre-Motor Circuit Activity and
Movement in a Drosophila Model of KCNMA1-Linked Dyskinesia. Mov Disord.
2021;36(5):1158-1169. doi:10.1002/mds.28479

25. Geissmann Q, Garcia Rodriguez L, Beckwith EJ, Gilestro GF. Rethomics: An R
framework to analyse high-throughput behavioural data. PLoS One. 2019;14(1):e0209331.
Published 2019 Jan 16. doi:10.1371/journal.pone.0209331

Manjila SB, Hasan G. Flight and Climbing Assay for Assessing Motor Functions in
Drosophila. Bio Protoc. 2018;8(5):e2742. Published 2018 Mar 5. doi:10.21769/BioProtoc.2742
27. Du W, Vidal M, Xie JE, Dyson N. RBF, a novel RB-related gene that regulates E2F
activity and interacts with cyclin E in Drosophila. Genes Dev. 1996;10(10):1206-1218.
doi:10.1101/gad.10.10.1206

Taylor-Harding B, Binné UK, Korenjak M, Brehm A, Dyson NJ. p55, the Drosophila
ortholog of RbAp46/RbAp48, is required for the repression of dE2F2/RBF-regulated genes.
Mol Cell Biol. 2004;24(20):9124-9136. doi:10.1128/MCB.24.20.9124-9136.2004

- Weng L, Zhu C, Xu J, Du W. Critical role of active repression by E2F and Rb proteins
 in endoreplication during Drosophila development. EMBO J. 2003;22(15):3865-3875.
 doi:10.1093/emboj/cdq373
- 30. Leader DP, Krause SA, Pandit A, Davies SA, Dow JAT. FlyAtlas 2: a new version of
- the Drosophila melanogaster expression atlas with RNA-Seq, miRNA-Seq and sex-specific
- 816 data. Nucleic Acids Res. 2018;46(D1):D809-D815. doi:10.1093/nar/gkx976
- 817 31. Davie, K., et al., A Single-Cell Transcriptome Atlas of the Aging Drosophila Brain. Cell,
- 818 2018. **174**(4): p. 982-998 e20.
- 819 32. Popova MK, He W, Korenjak M, Dyson NJ, Moon NS. Rb deficiency during Drosophila
- 820 eye development deregulates EMC, causing defects in the development of photoreceptors
- 821 and cone cells. J Cell Sci. 2011;124(Pt 24):4203-4212. doi:10.1242/jcs.088773
- 33. Du W, Dyson N. The role of RBF in the introduction of G1 regulation during Drosophila
 embryogenesis. EMBO J. 1999;18(4):916-925. doi:10.1093/emboj/18.4.916
- 824 34. Nériec N, Desplan C. From the Eye to the Brain: Development of the Drosophila Visual
- 825 System. Curr Top Dev Biol. 2016;116:247-271. doi:10.1016/bs.ctdb.2015.11.032
- 826 35. Pentimalli F, Forte IM, Esposito L, et al. RBL2/p130 is a direct AKT target and is
- required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines.
- 828 Oncogene. 2018;37(27):3657-3671. doi:10.1038/s41388-018-0214-3
- 829 36. Moon NS, Di Stefano L, Dyson N. A gradient of epidermal growth factor receptor
- signaling determines the sensitivity of rbf1 mutant cells to E2F-dependent apoptosis. Mol Cell
- 831 Biol. 2006;26(20):7601-7615. doi:10.1128/MCB.00836-06
- 832 37. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220-
- 833 5227. doi:10.1038/sj.onc.1209615
- 834 38. Lee PT, Zirin J, Kanca O, et al. A gene-specific T2A-GAL4 library for Drosophila. Elife.
- 835 2018;7:e35574. Published 2018 Mar 22. doi:10.7554/eLife.35574

39. Sainz de la Maza D, Hof-Michel S, Phillimore L, Bökel C, Amoyel M. Cell-cycle exit
and stem cell differentiation are coupled through regulation of mitochondrial activity in the
Drosophila testis. Cell Rep. 2022;39(6):110774. doi:10.1016/j.celrep.2022.110774

40. McGuire SE, Le PT, Osborn AJ, Matsumoto K, Davis RL. Spatiotemporal rescue of
memory dysfunction in Drosophila. Science. 2003;302(5651):1765-1768.
doi:10.1126/science.1089035

- 41. Sáenz-Farret M, Lang AE, Kalia L, et al. Spastic Paraplegia Type 7 and Movement Disorders: Beyond the Spastic Paraplegia. Mov Disord Clin Pract. 2022;9(4):522-529.
- 844 Published 2022 Apr 1. doi:10.1002/mdc3.13437

42. Pascual B, de Bot ST, Daniels MR, et al. "Ears of the Lynx" MRI Sign Is Associated with SPG11 and SPG15 Hereditary Spastic Paraplegia. AJNR Am J Neuroradiol. 2019;40(1):199-

847 203. doi:10.3174/ajnr.A5935

43. Accogli A, Zaki MS, Al-Owain M, et al. Lunapark deficiency leads to an autosomal
recessive neurodevelopmental phenotype with a degenerative course, epilepsy and distinct
brain anomalies. Brain Commun. 2023;5(5):fcad222. Published 2023 Aug 17.
doi:10.1093/braincomms/fcad222

44. Agarwal A, Oinam R, Goel V, et al. "Ear of the Lynx" Sign in Hereditary Spastic
Paraparesis (HSP) 76. Mov Disord Clin Pract. 2022;10(1):120-123. Published 2022 Nov 17.
doi:10.1002/mdc3.13606

45. Estiar MA, Leveille E, Spiegelman D, et al. Clinical and genetic analysis of ATP13A2 in
hereditary spastic paraplegia expands the phenotype. Mol Genet Genomic Med.
2020;8(3):e1052. doi:10.1002/mgg3.1052

46. Claudio PP, Howard CM, Baldi A, et al. p130/pRb2 has growth suppressive properties
similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer
Res. 1994;54(21):5556-5560.

47. Qi H, Dong C, Chung WK, Wang K, Shen Y. Deep Genetic Connection Between Cancer
and Developmental Disorders. Hum Mutat. 2016;37(10):1042-1050. doi:10.1002/humu.23040

- 863 48. Zappia MP, Rogers A, Islam ABMMK, Frolov MV. Rbf Activates the Myogenic
- Transcriptional Program to Promote Skeletal Muscle Differentiation. Cell Rep. 2019;26(3):702-
- 865 719.e6. doi:10.1016/j.celrep.2018.12.080
- 49. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol.
- 867 2002;3(1):11-20. doi:10.1038/nrm714
- 868

Family ID	HPO codes	F1	F1	F2	F3	F3	F4	F5	F5	F6	F7	F8	F8	F9	F9	F9	F10	F11	F11	F12	F12	F13	F14	Literature review	Total
Patients		P1	P2	P3	Ρ4	P5	P6	P7	P8	P9	P10	P11	P12	P13	P14	P15	P16	P17	P18	P19	P20	P21	P22	P23-28	P1-P28
Gender		F	Μ	F	F	F	F	Μ	Μ	Μ	F	М	Μ	М	Μ	Μ	Μ	F	F	F	Μ	F	Μ	3F, 3M	12F, 15M
Age range (years)		16- 20	16- 20	10- 15	16- 20	10- 15	0-5	6- 10	0- 5	0-5	10- 15	21- 25	26- 30	16- 20	10- 15	0-5	6- 10	16- 20	6- 10	0-5	6- 10	10- 15	0-5	6-36	2-36
Feeding difficulties	HP:0011968	-	-	+	+	+	-	-	-	-	+	-	-	-	-	-	-	n/a	n/a	+	+	n/a	+	n/a	7/19
FTT	HP:0001508	-	-	-	+	+	-	+	+	-	-	n/a	n/a	n/a	n/a	n/a	n/a	-	-	n/a	n/a	n/a	-	1/1	5/14
Microcephaly	HP:0005484	+	+	+	+	+	+	+	+	+	+	-	-	+	+	+	n/a	+	+	-	-	+	-	4/6	20/27
Hypotonia in infancy	HP:0008947	+	+	+	+	+	+	-	-	+	+	+	+	+	+	+	+	+	+	+	+	+	+	6/6	26/28
GDD	HP:0001270	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	6/6	28/28
Non- ambulatory	HP:0002540	+	+	-	+	+	+	+	+	+	-	-	-	-	+	+	+	+	+	+	n/a	+	+	4/5	20/26
Gait abnormalities	HP:0001288	n/a	n/a	+	n/a	n/a	n/a	-	-	-	+	+	+	+	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	3/3	8/11
Absent speech	HP:0001344	+	+	-	+	+	+	+	+	n/a	+	-	-	+	+	+	+	+	+	+	+	+	+	4/6	22/27
ID +Moderate ++Severe +++ Profound	HP:0001249	++	++	+++	+++	+++	+	+	+	n/a	++	++	++	++	++	++	++	+++	+++	++	++	++	+++	++ 5/6 +++ 1/6	+ 3/27 ++ 17/27 +++ 7/27
ID +Moderate ++Severe +++ Profound Muscle weakness	HP:0001249 HP:0001324	++	++	+++	+++	+++	+	+	+	n/a -	++	++	++	++	++	++	++	+++	+++	++	++	++	+++	++ 5/6 +++ 1/6 n/a	+ 3/27 ++ 17/27 +++ 7/27 12/22
ID +Moderate ++Severe +++ Profound Muscle weakness Hypotonia	HP:0001249 HP:0001324 HP:0001252	++ + +	++ + -	++++ + + +	++++ + + +	++++ + + +	+ + + +	+	+	n/a - n/a	++	++	++	++	++	++	++ + +	+++	++++ + -	++ + + +	++ + +	++	++++ + +	++ 5/6 +++ 1/6 n/a n/a	+ 3/27 ++ 17/27 +++ 7/27 12/22 10/21
ID +Moderate ++Severe +++ Profound Muscle weakness Hypotonia Hypertonia	HP:0001249 HP:0001324 HP:0001252 HP:0001276	++ + + -	++ + - +	++++ + + -	++++ + + -	++++ + + -	+ + + -	+	+	n/a - n/a n/a	++	++	++	++	++	++	++ + + -	++++ + - +	++++ + - +	++ + + -	++ + + -	++	++++ + + -	++ 5/6 +++ 1/6 n/a n/a	+ 3/27 ++ 17/27 +++ 7/27 12/22 10/21 6/21
ID +Moderate ++Severe +++ Profound Muscle weakness Hypotonia Hypertonia Dystonia	HP:0001249 HP:0001324 HP:0001252 HP:0001276 HP:0001332	++ + +	++ + - + + + + + + +	++++ + +	++++ + + + + + + + + + + +	++++ + + + + + + + + + +	+ + + +	+	+	n/a - n/a +	++	++	++	++	++	++	++ + + - n/a	++++ + +	++++ + +	++ + + + + + + + + + + +	++ + + + + + + + + + + +	++	++++ + + + + + + + + + + +	++ 5/6 +++ 1/6 n/a n/a n/a n/a	+ 3/27 ++ 17/27 +++ 7/27 12/22 10/21 6/21 7/21
ID +Moderate ++Severe +++ Profound Muscle weakness Hypotonia Hypertonia Dystonia Tremor	HP:0001249 HP:0001324 HP:0001252 HP:0001276 HP:0001332 HP:0001337	++ + +	+++ + - + + + + + + + + + + + + + + + +	++++ + + +	++++ + + - + +	++++ + + - + +	+ + + + + +	+	+	n/a - n/a + -	++	++	++	++	++	++	++ + - n/a n/a	++++ +	++++ + - - -	++ + + + + + -	++ + + + + + -	++ + + +	++++ + + - + -	++ 5/6 +++ 1/6 n/a n/a n/a n/a n/a	+ 3/27 ++ 17/27 +++ 7/27 12/22 10/21 6/21 6/21
ID +Moderate ++Severe +++ Profound Muscle weakness Hypotonia Hypertonia Dystonia Tremor Behavioural abnormalities	HP:0001249 HP:0001324 HP:0001252 HP:0001332 HP:0001337 HP:000708	++ +	+++ + - + + + + + +	++++ + - - + +	++++ + + + + + + +	++++ + + + + + + + +	+ + + + + + + + + + + + + + + + + +	+ +	+ +	n/a - n/a + -	+++ - - - - - +	+++	+++ - - - - - - +	+++ - - - - - +	+++ - - + - - -	+++	+++ + - n/a +	++++ + - - - +	++++ + - - - - +	++ + + + + + - +	++ + + + + + - + + + + + + + + + + + +	+++ - - + - + + + +	++++ + - + - -	++ 5/6 +++ 1/6 n/a n/a n/a n/a n/a 6/6	+ 3/27 ++ 17/27 +++ 7/27 12/22 10/21 6/21 7/21 6/21 24/28
ID +Moderate ++Severe +++ Profound Muscle weakness Hypotonia Hypertonia Dystonia Tremor Behavioural abnormalities Stereotypies	HP:0001249 HP:0001324 HP:0001252 HP:0001332 HP:0001337 HP:0000708 HP:0100022	++ +	+++ + - + + + + + + + +	++++ + - - + + +	++++ + + + + + + + + + +	++++ + + + + + + + + + +	+ + - - + + +	+ + -	+	n/a - n/a + - -	+++ - - - - + + + +	++	+++ - - - - - + -	+++ - - - - - + -	+++ - - + - - + + -	+++ - - + - - - + -	+++ + - n/a + +	++++ + - - - + + +	++++ + - - - + + +	++ + +	+++ + - + - + + +	+++ - - + + + + +	++++ + - + - + + +	++ 5/6 +++ 1/6 n/a n/a n/a n/a 6/6 3/3	+ 3/27 ++ 17/27 +++ 7/27 12/22 10/21 6/21 7/21 6/21 24/28 15/25
ID +Moderate ++Severe +++ Profound Muscle weakness Hypotonia Hypertonia Dystonia Tremor Behavioural abnormalities Stereotypies Seizures	HP:0001249 HP:0001324 HP:0001252 HP:0001332 HP:0001337 HP:0000708 HP:0100022 HP:0001250	+++ + +	+++ + + + + + + + + + +	++++ + - - + + + +	++++ + + + + + + + + +	++++ + + + + + + + + +	+ + - - + + + + +	+	+ + - + - +	n/a - n/a + - - -	+++ - - - - + + + +	++	+++ - - - - - + -	+++ - - - - - + -	+++ - - - - - - - - - -	+++ - - - - - - - - - -	+++ + - n/a n/a + +	++++ + - - - + + + -	++++ + - + - - + + + +	+++ + + + +	+++ + - + + - + + + +	+++ - - + + + + + + + -	++++ + - + + - + + -	++ 5/6 +++ 1/6 n/a n/a n/a n/a 6/6 3/3 3/6	+ 3/27 ++ 17/27 +++ 7/27 12/22 10/21 6/21 7/21 6/21 24/28 15/25 10/28

Table 1 Overview of the clinical features observed in the cohort.

Abnormalities																									
Ophthalmic features	HP:0000478	+	-	-	+	+	+	+	+	+	+	-	-	-	-	-	-	-	-	-	-	+	n/a	5/6	14/27



■Yes ■No ■NA

В







Patient images redacted as per MedRxiv policy

В











